Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin

In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagli...

Source: Cardiovascular Diabetology - September 13, 2017 Category: Cardiology Authors: Pia S. Pollack, Kristina D. Chadwick, David M. Smith, Martin Billger, Boaz Hirshberg, Nayyar Iqbal and David W. Boulton Tags: Review Source Type: research